{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:31Z","timestamp":1791388111474,"version":"4.3.3"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T00:00:00Z","timestamp":1383091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Incyte Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,2,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Polycythemia vera (PV) is a myeloproliferative neoplasm associated with somatic gain\u2010of\u2010function mutations of <jats:italic>Janus<\/jats:italic> <jats:italic>kinase\u20102<\/jats:italic> (<jats:italic>JAK2<\/jats:italic>). Therapeutic options are limited in patients with advanced disease. Ruxolitinib, an oral JAK1\/JAK2 inhibitor, is active in preclinical models of PV. The long\u2010term efficacy and safety of ruxolitinib in patients with advanced PV who are refractory or intolerant to hydroxyurea were studied in a phase 2 trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Response was assessed using modified European LeukemiaNet criteria, which included a reduction in hematocrit to &lt;\u200945% without phlebotomy, resolution of palpable splenomegaly, normalization of white blood cell and platelet counts, and reduction in PV\u2010associated symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Thirty\u2010four patients received ruxolitinib for a median of 152 weeks (range, 31 weeks\u2010177 weeks) or 35.0 months (range, 7.1 months\u201040.7 months). Hematocrit &lt;\u200945% without phlebotomy was achieved in 97% of patients by week 24. Only 1 patient required a phlebotomy after week 4. Among patients with palpable splenomegaly at baseline, 44% and 63%, respectively, achieved nonpalpable spleen measurements at weeks 24 and 144. Clinically meaningful improvements in pruritus, night sweats, and bone pain were observed within 4 weeks of the initiation of therapy and maintained with continued treatment. Ruxolitinib treatment also reduced elevated levels of inflammatory cytokines and granulocyte activation. Thrombocytopenia and anemia were the most common adverse events. Thrombocytopenia of\u2009\u2265\u2009grade 3 or anemia of\u2009\u2265\u2009grade 3 (according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0) occurred in 3 patients each (9%) (1 patient had both) and were managed with dose modification.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Ruxolitinib was generally well tolerated and provided rapid and durable clinical benefits in patients with advanced PV who were refractory or intolerant to hydroxyurea. <jats:bold><jats:italic>Cancer<\/jats:italic> 2014;120:513\u201320.<\/jats:bold> \u00a9 2013 The Authors published by Wiley Periodicals, Inc. on behalf of American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28441","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T12:32:55Z","timestamp":1383136375000},"page":"513-520","source":"Crossref","is-referenced-by-count":158,"title":["A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea"],"prefix":"10.1002","volume":"120","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[{"name":"Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Ospedali di Circolo e Fondazione Macchi  Varese Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Tower Cancer Research Foundation Beverly Hills California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gattoni","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale Santo Spirito Casale Monferrato Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pieri","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Elena","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui","family":"He","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Contel","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijoyesh","family":"Mookerjee","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sandor","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia Italy"},{"name":"Department of Molecular Medicine, University of Pavia Pavia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23135"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328955"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22026"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404810"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08019.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-176818"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478891"},{"key":"e_1_2_7_19_1","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program.Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed August 15 2013."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.4282"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","unstructured":"TurlureP.Complete hematological molecular and histological remissions without cytoreductive treatment lasting after pegylated\u2010interferon \u03b1\u20102a (peg\u2010IFN\u03b1\u20102a) therapy in polycythemia vera (PV): long term results of a phase 2 trial [abstract]. Presented in abstract form at: American Society of Hematology Annual Meeting and Exposition; December 10\u201012 2011; San Diego CA. Abstract 280.","DOI":"10.1182\/blood.V118.21.280.280"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.062"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.148"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208500"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-121434"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-042515"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01548.x"},{"key":"e_1_2_7_31_1","unstructured":"VerstovsekS MesaRA GotlibJ et al.Efficacy safety and survival with ruxolitinib treatment in patients with myelofibrosis results of a median 2-year follow-up of COMFORT-I.Haematologica.2013Sept 13. Epub ahead of print. PMID 24038026."},{"key":"e_1_2_7_32_1","doi-asserted-by":"crossref","unstructured":"CervantesF KiladjianJJ NiederwieserD et al.Long\u2010term safety efficacy and survival findings from COMFORT\u2010II a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Presented in abstract form at: American Society of Hematology Annual Meeting and Exposition; December 8\u201011 2012; Atlanta GA. Abstract 801.","DOI":"10.1182\/blood.V120.21.801.801"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28441","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28441","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.28441","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:26:23Z","timestamp":1760264783000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,30]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2,15]]}},"alternative-id":["10.1002\/cncr.28441"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28441","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,30]]}}}